Comprehensive Evaluation of Transcriptome-based Cell-type Quantification Methods for Immuno-oncology
Overview
Authors
Affiliations
Motivation: The composition and density of immune cells in the tumor microenvironment (TME) profoundly influence tumor progression and success of anti-cancer therapies. Flow cytometry, immunohistochemistry staining or single-cell sequencing are often unavailable such that we rely on computational methods to estimate the immune-cell composition from bulk RNA-sequencing (RNA-seq) data. Various methods have been proposed recently, yet their capabilities and limitations have not been evaluated systematically. A general guideline leading the research community through cell type deconvolution is missing.
Results: We developed a systematic approach for benchmarking such computational methods and assessed the accuracy of tools at estimating nine different immune- and stromal cells from bulk RNA-seq samples. We used a single-cell RNA-seq dataset of ∼11 000 cells from the TME to simulate bulk samples of known cell type proportions, and validated the results using independent, publicly available gold-standard estimates. This allowed us to analyze and condense the results of more than a hundred thousand predictions to provide an exhaustive evaluation across seven computational methods over nine cell types and ∼1800 samples from five simulated and real-world datasets. We demonstrate that computational deconvolution performs at high accuracy for well-defined cell-type signatures and propose how fuzzy cell-type signatures can be improved. We suggest that future efforts should be dedicated to refining cell population definitions and finding reliable signatures.
Availability And Implementation: A snakemake pipeline to reproduce the benchmark is available at https://github.com/grst/immune_deconvolution_benchmark. An R package allows the community to perform integrated deconvolution using different methods (https://grst.github.io/immunedeconv).
Supplementary Information: Supplementary data are available at Bioinformatics online.
AI Model for Predicting Anti-PD1 Response in Melanoma Using Multi-Omics Biomarkers.
Gschwind A, Ossowski S Cancers (Basel). 2025; 17(5).
PMID: 40075562 PMC: 11899402. DOI: 10.3390/cancers17050714.
Advancements in proteogenomics for preclinical targeted cancer therapy research.
Suo Y, Song Y, Wang Y, Liu Q, Rodriguez H, Zhou H Biophys Rep. 2025; 11(1):56-76.
PMID: 40070661 PMC: 11891078. DOI: 10.52601/bpr.2024.240053.
Comprehensive analysis of TMEM9 in human tumors.
Zhang X, Zhou L, Wei S, Zhang X Discov Oncol. 2025; 16(1):276.
PMID: 40053281 PMC: 11889325. DOI: 10.1007/s12672-025-02040-1.
Shang J, Jiang H, Zhao Y, Yang J, Lin Y, Zhang N J Transl Med. 2025; 23(1):263.
PMID: 40038757 PMC: 11877874. DOI: 10.1186/s12967-025-06316-6.
De Lucia A, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C Front Immunol. 2025; 16:1515748.
PMID: 39995659 PMC: 11847692. DOI: 10.3389/fimmu.2025.1515748.